December 5, 2008: Proteus Biomedical Inc., a pioneer in intelligent medicine, has been selected a 2009 Technology Pioneer by the World Economic Forum.
The Technology Pioneer Award honors 34 visionary companies from around the world that a panel of 44 global technology experts believes will have a deep impact on business and society. To be selected, a company must be involved in the development of life-changing technology innovation, demonstrate visionary leadership, and show signs of being a long-standing market leader.
“Proteus has developed a unique approach to personalizing therapy,” said Andrew Thompson, Proteus CEO and co-founder. “We embed micro-sensors into existing drugs and devices, which transmit information, securely, to a person’s cell phone via the Internet. A person can understand how their body is responding to their therapy, and, if they choose, share this information with a family member, physician or friend to help them stay healthy. We are delighted that the World Economic Forum has recognized the immense potential of this approach and look forward to actively participating in their programs.”
“We congratulate Proteus Biomedical for their remarkable achievements and welcome them to the wider community of the World Economic Forum. During these difficult times, we are certain that the technologies driven by these visionary companies will contribute to the next wave of growth, with the innovative and entrepreneurial spirit that characterizes them,” said André Schneider, managing director and chief operating officer of the World Economic Forum.
As a 2009 Technology Pioneer, Proteus Biomedical has been invited to participate in the World Economic Forum’s Annual Meeting in Davos-Klosters, Switzerland, Jan. 28 through Feb. 1, 2009 and the Annual Meeting of the New Champions in Dalian, China, Sept. 10-12. These two events bring together the world’s foremost thought leaders in business and government.
Proteus Biomedical’s tiny protected electronics inside of implanted medical device leads enable advanced monitoring and adjustment of resynchronization therapy for heart failure patients. (Photo: Businesswire)